CLINICOPATHOLOGICAL FEATURES AND CD20 EXPRESSION IN B-CELL NON-HODGKIN LYMPHOMA
Main Article Content
Abstract
Background: B-cell Non-Hodgkin lymphoma exhibits a wide histological spectrum with various subtypes, each characterized by distinct pathological features and differing CD20 expression levels. Objectives: To identify the pathological characteristics and CD20 expression in B-cell non-Hodgkin lymphoma. Materials and methods: A case study involving 35 cases that met the inclusion criteria at Can Tho Oncology Hospital. Results: The average age of the study subjects was 58.9 years, with a higher incidence in males. B symptoms were present in 25.7% of cases, ECOG ≥ 2 in 20.0%, elevated serum LDH in 62.9%, and bone marrow infiltration in 8.6%. The most common histological subtype was diffuse large B-cell lymphoma (65.7%). Most cases were in stage III (54.3%), with the majority being in the low to intermediate-risk group according to the IPI (34.3%). CD20 over-expression was 65.7%. Conclusions: No association was observed between CD20 expression and the pathological features of B-cell non-Hodgkin lymphoma.
Article Details
Keywords
B-cell non-Hodgkin lymphoma, histopathology, immunohistochemistry, CD20
References
2. Phạm Xuân Dũng và cộng sự. Kết quả ghi nhận quần thể ung thư tại thành phố Hồ Chí Minh năm 2016. Tạp chí Ung thư học Việt Nam. 2019.1(5), 23-29.
3. Phạm Xuân Dũng và cộng sự. Tỷ lệ tử vong do ung thư tại thành phố Hồ Chí Minh năm 2017. Tạp chí Ung thư học Việt Nam. 2020.1(5),13-20.
4. Smith A., Crouch S., Lax S., et al. Lymphoma incidence, survival and prevalence 2004-2014:
sub-type analyses from the UK's Haematological Malignancy Research Network. Br J Cancer. 2015.112(9),1575-1584. doi:10.1038/bjc.2015.94
5. Phạm Duy Mạnh, Trịnh Lê Huy. Kết quả hoá trị phác đồ R-CHOP bệnh u lympho không Hodgkin tế bào B lớn lan tỏa. VMJ. 2021.505(2), 118-123. doi:10.51298/vmj.v505i2.1105.
6. Choi C.H., Park Y.H., Lim J.H., et al. Prognostic Implication of Semi-quantitative Immunohistochemical Assessment of CD20 Expression in Diffuse Large B-Cell Lymphoma. J Pathol Transl Med. 2016.50(2), 96-103. doi:10.4132/jptm.2016.01.12.
7. Quách Châu Tài, Trần Thanh Tùng. Đánh giá hiệu quả điều trị lymphoma không Hodgkin dòng tế bào B trên người cao tuổi tại Bệnh viện Chợ Rẫy. VMJ. 2021.505(2), 106-110. doi:10.51298/vmj.v505i2.1102.
8. Suzuki Y., Yoshida T., Wang G., et al. Association of CD20 levels with clinicopathological parameters and its prognostic significance for patients with DLBCL. Ann Hematol. 2012.91(7), 997-1005. doi:10.1007/s00277-012-1407-4.
9. Schmidt C., Fingerle-Rowson G., Boehme A., et al. Changes in the diagnosis and treatment of patients with low grade lymphoma in Germany: years 2006-2009. Leuk Lymphoma. 2015.56(3), 694-702. doi:10.3109/10428194.2014.928935.
10. Johnson N.A., Boyle M., Bashashati A., et al. Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood. 2009. 113(16), 3773-3780. doi:10.1182/blood-2008-09-177469.
11. Sehn L.H., Berry B., Chhanabhai M., et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007. 109(5), 1857-1861. doi:10.1182/blood-2006-08038257.